Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Sponsors
Dizal (Jiangsu) Pharmaceutical Co. Ltd., Swiss Group for Clinical Cancer Research, Rheinische Friedrich-Wilhelms-Universitaet Bonn
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion MutationN2)ResectableStage IIA/B seminomalocally advanced non-small cell lung cancer (NSCLCresectable and borderline resectable stage IIIA/B NSCLC
Phase 2
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.
Active, not recruitingCTIS2023-504536-18-00
Start: 2024-07-31Target: 10Updated: 2025-10-22
SAKK 01/18: Reduced intensity radio-chemotherapy for Stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts
Active, not recruitingCTIS2023-509663-24-00
Start: 2020-08-20Target: 95Updated: 2025-03-07
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Durvalumab (MEDI4736) in resectable and borderline resectable stage IIIA/B NSCLC
RecruitingCTIS2024-516367-80-00
Start: 2025-04-24Target: 176Updated: 2025-10-10